269 related articles for article (PubMed ID: 31577671)
21. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
23. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B
Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937
[TBL] [Abstract][Full Text] [Related]
25. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
26. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
27. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
[TBL] [Abstract][Full Text] [Related]
28. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
30. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
31. Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation.
Gerhardt T; Terjung B; Knipper P; Palmedo H; Woitas RP; Kalff J; Sauerbruch T; Spengler U
Eur J Med Res; 2009 May; 14(5):210-5. PubMed ID: 19541578
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
33. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.
Cotterell AH; Fisher RA; King AL; Gehr TW; Dawson S; Sterling RK; Stravitz RT; Luketic VA; Sanyal AJ; Shiffman ML; Posner MP
Clin Transplant; 2002; 16 Suppl 7():49-51. PubMed ID: 12372044
[TBL] [Abstract][Full Text] [Related]
36. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Neuhaus P; Gotthardt D; Loss M; Ladenburger S; Paulus EM; Mertens M; Schlitt HJ
Am J Transplant; 2014 Mar; 14(3):701-10. PubMed ID: 24502384
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
[TBL] [Abstract][Full Text] [Related]
38. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
40. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up.
Heeg MH; Mueller GA; Bramlage C; Homayounfar K; Muehlhausen J; Leha A; Koziolek MJ
Transplant Proc; 2013; 45(1):142-7. PubMed ID: 23375288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]